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Newmolecular diagnostic tools have recently allowed the discovery of human rhinovirus species C (HRV-
C) that may be overrepresented in children with lower respiratory tract complications. Unlike HRV-A and
HRV-B, HRV-C cannot be propagated in conventional immortalized cell lines and their biological
properties have been difﬁcult to study. Recent studies have described the successful ampliﬁcation of
HRV-C15, HRV-C11, and HRV-C41 in sinus mucosal organ cultures and in fully differentiated human
airway epithelial cells. Consistent with these studies, we report that a panel of clinical HRV-C specimens
including HRV-C2, HRV-C7, HRV-C12, HRV-C15, and HRV-C29 types were all capable of mediating
productive infection in reconstituted 3D human primary upper airway epithelial tissues and that the
virions enter and exit preferentially through the apical surface. Similar to HRV-A and HRV-B, our data
support the acid sensitivity of HRV-C. We observed also that the optimum temperature requirement
during HRV-C growth may be type-dependent.
& 2013 Elsevier Ltd. All rights reserved.Introduction
Human rhinoviruses (HRVs) are classiﬁed into three species
(HRV-A, -B and -C) based on capsid sequence relatedness (Laine
et al., 2006; Ledford et al., 2004; Savolainen et al., 2002). By contrast
to their closest relatives, the human enteroviruses (HEVs), which
can cause disseminated disease and affect multiple organs including
the central nervous system, HRVs infect primarily the upper
respiratory tract. This restricted tropism is in part attributed to
temperature constraints needed for optimal growth and acid
sensitivity. HRVs and HEVs present different optimal growth tem-
perature in vitro. HEVs grow better at 37 1C, whereas most HRVs
grow best at 33 1C, the temperature of the upper airways. Further-
more, compared to HEVs, HRVs are sensitive to acidic pH and do not
survive the gastrointestinal acidic environment. Although acid
sensitivity seems related to capsid stability (Skern et al., 1991), the
genotypic determinants of temperature adaptation are not known.
We highlighted a higher GC content among HEVs than among HRVs
(Tapparel et al., 2007). Whether a causative relationship exists
between this feature and temperature adaptation remains to bell rights reserved.
pparel).demonstrated. However, temperature and acid sensitivity may not
be true for all HRVs. Some HRV types were shown to grow equally
or even better at 37 1C (Papadopoulos et al., 1999) and an increasing
number of reports have found HRV nucleic acids in stools (Harvala
et al., 2012; Lau et al., 2012), while Honkanen et al. could even
isolate the virus in stool samples of young children (Honkanen
et al., 2012). These ﬁndings suggest that at least some HRV types are
able to survive both the higher temperature and acidic environment
found in the gastrointestinal tract.
HRV-C was identiﬁed in 2006 (Arden et al., 2006; Gerna et al.,
2007; Kiang et al., 2007; Kistler et al., 2007; Lamson et al., 2006; Lau
et al., 2007; Lee et al., 2007; McErlean et al., 2008; McErlean et al.,
2007; Renwick et al., 2007) and revealed to have been circulating for
hundreds of years in humans (Briese et al., 2008; Huang et al., 2009;
Wisdom et al., 2009). Epidemiological studies have shown that HRV-
As are the most prevalent rhinoviruses in human infections (45% to
65% of cases), closely followed by HRV-Cs (30% to 50%) and HRV-Bs
(2% to 13%) (Arakawa et al., 2012; Harvala et al., 2012; Onyango et al.,
2012; Tapparel et al., 2011; Wisdom et al., 2009). Reports suggest that
HRV-Cs may be overrepresented in children with pneumonia or
acute wheezing and exacerbation of asthma, suggesting an associa-
tion between HRV-C infection and lower respiratory tract complica-
tions (Lau et al., 2010; Lau et al., 2007; Miller et al., 2009; Tapparel
et al., 2009b; Wisdom et al., 2009). Disseminated HRV-C infections
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Tapparel et al., 2011). However, strong evidence is lacking to
deﬁnitely claim that HRV-Cs might be more virulent or more adapted
to the lower airway environment (Iwane et al., 2011; Lee et al., 2012;
Tapparel et al., 2011).
To better appreciate HRV-C biological properties and pathogen-
esis, functional culture systems are needed since this virus does
not grow in standard cell lines. Three studies have recently
described the successful ampliﬁcation of HRV-C15 clinical speci-
men in sinus mucosal organ cultures (Bochkov et al., 2011), HRV-
C15 and HRV-C11 generated from infectious clones in fully
differentiated human airways' epithelial cells (nasal or bronchial
epithelial) (Hao et al., 2012), and HRV-C15 and HRV-C41clinical
specimens in differentiated sinus epithelial cells (Ashraf et al.,
2012). The effects of antibodies directed against HRV major
(intercellular adhesion molecule-1 [ICAM1]) or minor group (low
density lipoprotein receptor [LDLR]) receptors on HRV-C replica-
tion were assessed in these culture models and conﬁrm that HRV-
Cs use a different receptor. Furthermore, Ashraf et al. showed that
two HRV-C types (HRV-C15 and HRV-C41), although similar to
HRV-A and -B viruses in relation to acid sensitivity, displayed
similar growth efﬁciency at 341 and 37 1C, suggesting that this HRV
species may be more adapted to the lower airway temperature.
In this study, we used commercially available, 3D human upper
airway epithelia reconstituted in vitro (MucilAir™, Epithelix,
Geneva, Switzerland) to extend these observations using HRV-C
infected clinical specimens. We found that this primary air–liquid
interface (ALI) culture system supports successful growth of
eight out of eight tested clinical strains, representing ﬁve different
HRV-C types (HRV-C2, -C15, -C29, -C12 and -C7). We demonstrate
also that HRV-Cs enter and exit preferentially at the apical side
of this ALI culture system. Finally, we conﬁrm the acid sensitivity
of HRV-Cs and show that temperature sensitivity may be type-
dependent.Results
Different HRV-C types grow in air–liquid interface (ALI) Human
airway epithelia reconstituted in vitro (MucilAir™)
Among upper respiratory tract samples collected from patients
of the University of Geneva Hospitals, screened positive for HRV
infection and typed based on VP4/VP2 sequencing, seven speci-
mens infected with HRV-C viruses and one (WW74-1202-U) with
HRV-A41 were used for this study. A phylogenetic tree based on
the VP4/VP2 sequence of these HRV-C clinical strains and on
corresponding sequences of HRV-C reference types (http://www.
picornastudygroup.com/types/enterovirus/hrv-c.htm) shows that
these selected strains were distributed among ﬁve distantly
related HRV genotypes (HRV-C2, -C7, -C12, -C15 and -C29
[Fig. 1]). The calculated VP4/VP2 nucleotide sequence homology
for each of them with the closest reference type ranges from 92.1%
to 97% (Table 1). Each of these HRV-C clinical samples, HRV-A41
clinical sample, and HRV-A16 stock was inoculated on ALI human
airway epithelia reconstituted in vitro (named thereafter Muci-
lAir™ for simplicity), and the HRV RNA load was quantiﬁed at the
apical surface at different times post-inoculation by real-time RT-
PCR (Schibler et al., 2012b; Tapparel et al., 2009a). The RNA load
present in the HRV inoculum is indicated for each clinical speci-
men (Fig. 2). The RNA level observed at the apical surface after the
6 h incubation period (presumably before virion production) and
after repeated PBS washes was considered as a reference back-
ground level for each specimen analyzed. Eight out of eight clinical
strains tested, as well as HRV-A16, display replication in MucilAir™
with a maximum RNA load observed between 24 h and 72 h(Fig. 2). The increase in cell-associated virus tested for the HRV-
C29 specimen also revealed signiﬁcant replication with a max-
imum yield observed for an inoculum of 105.4 HRV copies (Fig. 3).
Of note, this inoculum load represents RNA copies and may be an
overestimation of the number of fully competent virions present in
the clinical specimen. In addition, HRV-A16, HRV-C7, and HRV-C29
virions collected from the apical surface or from total tissue lysates
were subsequently passed and re-ampliﬁed in MucilAir™ (data not
shown). The presence of replicating virus was further conﬁrmed
by both immunoﬂuorescence and in situ hybridization on total
MucilAir™ or on parafﬁn-embedded tissue sections (Fig. 4). The
localization of infected cells conﬁrms that viral replication is
restricted to cells located at the apical surface of the MucilAir™
for both HRV-A and HRV-C (Fig. 4).
HRV-Cs enter and exit predominantly at the apical surface of the
human airway epithelium
To test the preferred HRV entry site in the polarized epithelium,
HRV-C7 and HRV-A16, were inoculated at the apical (tissue/air
interface) or at the basal (tissue/liquid interface) side of the
MucilAir™, respectively, and virus production was quantiﬁed by
real-time RT-PCR from both sides at different times post-infection.
Virus inoculation at the basal surface did not give rise to any viral
RNA production, neither from the apical nor the basal surface
(data not shown). By contrast, after apical inoculation of four
different HRV-C types, HRV RNA could be recovered from both the
apical and basal sides, but viral RNA was detected with higher and
more sustained loads in the apical compared to the basal surface of
the epithelium (Fig. 5). Of note, the higher load observed at the
apical surface is not linked to RNA leftover from apical inoculation
since inoculation by total immersion of the tissue in diluted
clinical specimen gave rise to the same observation (data not
shown). Furthermore, no HRV RNA could be found at 48 h after
apical inoculation with the same amount of acid-treated (Fig.5) or
UV-inactivated virus (data not shown).
HRV-Cs are sensitive to acidic pH, whereas temperature sensitivity
may be type-dependent
Clinical strains corresponding to HRV-C29 and HRV-A41, as well
as HRV-A16, were inoculated on MucilAir™ after pretreatment
with acidic (pH 4) or neutral (pH 7.2) solution. In parallel, a well
characterized HEV-A71 (HEV-A71 [EU414331]) was treated simi-
larly before Vero cell infection. Neither HRV-C29 and HRV-A41 nor
HRV-A16 were able to grow after acidic pretreatment, whereas
HEV-A71 grew efﬁciently independent of any acidic pretreatment
(Fig. 6).
The growths of HRV-C2, –C7,–C12 and –C29, as well as HRV-
A41 clinical strains, were compared at 341 and 37 1C. Fig. 7 shows
that HRV-C2 and –C12 strains present almost equivalent replica-
tion levels at both temperatures, similar to the HRV-A41 strain and
the HEV-A71 [EU414331] control tested on Vero cells (data not
shown). By contrast, HRV-C7 and HRV-C29 strains show a sig-
niﬁcant growth advantage at 34 1C 24 h post inoculation while this
growth advantage gets smaller at later time points. Of note, the
calculated GC content of each of these different viruses based on
the GenBank complete genome sequence of the nearest serotype
(if available) (Fig. 7) did not show a correlation with optimal
growth temperature in this experiment.
Discussion
The commercially available, reconstituted, MucilAir™ used in
this study allowed to investigate the biological properties of HRV-C
Fig. 1. Phylogenetic tree of the different HRV-Cs sequenced from the clinical samples used in this study. The VP4/VP2 nucleotide sequence (405 nt from the ORF start codon)
of HRV-C- positive clinical samples (in bold) and representatives of each of the 51 HRV-C reference types whose sequence is available in GenBank were included in the
phylogenetic analysis with enterovirus 68 (EV68, GenBank ID: AY426531) as the outgroup. Only bootstrap values 450 are indicated. Genbank ID of each Genbank available
sequence is indicated in brackets next to the sequence name.
Table 1
Identity of the different HRV-C clinical strains and nearest reference types. The percent of nucleotide homology between each clinical strain and the nearest reference types
are indicated. For Genbank ID, see Fig. 1.
GB09-
0909-U
WA11-
1201-U
HRV-
C12
SO7-
0909-U
HRV-
C15
HRV-
C2
VD11-
1202-U
WM12-
0212-U
HRV-
C7
WA23-
1203-U
HRV-
C29
KG11-
1202-U
GB09-0909-U 100
WA11-1201-U 97 100
HRV-C12 92.1 92.6 100
SO7-0909-U 74.6 74.3 75.1 100
HRV-C15 73.5 72.7 74.4 96.4 100
HRV-C2 74.6 74.6 72.8 76 74.9 100
VD11-1202-U 73.8 73.8 72.1 76.3 75.4 96 100
WM12-0212-U 73.8 73.8 72.1 76.3 75.4 96 100 100
HRV-C7 70.4 71.9 71.6 71.9 71.5 73.8 73.3 73.3 100
WA23-1203-U 70.4 71.9 71.1 70.9 70.7 74.1 73.3 73.3 96.5 100
HRV-C29 71.1 72.6 71.4 70.6 70 73.3 73.3 73.3 68.4 68.6 100
KG11-1202-U 70.2 71.7 71 71.6 71 73.1 73.1 73.1 68.8 69.3 97 100
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strains corresponding to ﬁve different HRV-C types and an HRV-
A41. These MucilAir™ present most of the morphological and
functional features of native tissues, such as the presence of basal,
mucus, and ciliated cells; secretion of cytokines, chemokines and
various proteases; active cilia beating and mucociliary clearance;
ion channel activity and electrophysiology [http://www.epithelix.com/content/view/6/5/lang,en]. In addition, these tissues are cul-
tured in ALI, which allows the study of the viral life cycle in the
context of a polarized tissue. Finally, the quality control performed
before tissue delivery and the reconstitution of human airway
epithelia from a pool of nasal polyp cells originating from different
donors reduce considerably the experimental variability observed
with organ cultures (Bochkov et al., 2011).
Fig. 2. Seven HRV-C strains corresponding to ﬁve distinct HRV-C types grow
successfully in ALI MucilAir™. HRV RNA load measured by real-time RT-PCR from
infected tissue supernatants collected at the apical surface of ALI MucilAir™
infected with one HRV-A and seven different HRV-C clinical samples, as well as a
HRV-A16 control. Each MucilAir™ was immersed in one ml of 10-fold diluted
clinical specimen and tissues were washed three times at 6 h post inoculation
before sample collection from the apical surface at the indicated time point. Input:
HRV RNA load present in the inoculum for each specimen.
Fig. 3. Dose response curve of HRV-C29 (KG11-1202-U) in MucilAir™. MucilAir™
was apically inoculated with three 20-fold serial dilutions of HRV-C29 clinical
specimen and cell-associated viral RNA was quantiﬁed immediately post-inocula-
tion (PI) and 24 h later. Error bars represent the standard deviation calculated from
biological replicates (n¼2).
Fig. 4. Localization of HRV infected cells in MucilAir™. Immunoﬂuorescence with
the mAbJ2 antibody detecting double-strand RNA (A and C) and in situ hybridiza-
tion with the Panenterhino/Ge/08 PNA probe (B) performed on total (A) or parafﬁn-
embedded tissue sections (B and C) of MucilAir™ infected for 72 h with the
indicated HRV-A41 and HRV-C strains, as well as HRV-A16 or non infected. HRV-
C7,–C12 and –C29 correspond respectively to clinical strains WA23-1203-U, GM09-
0909-U and KG11-1202-U. For each panel, the left column corresponds to labeling
with the antibody (A and C) or probe alone (B), whereas the right column
represents a merged image with DAPI coloration. The types used for infection are
indicated on the right of each line. The basal and apical sides of the tissue are
indicated in each merged image. Non inf: non infected.
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we observed no replication when the virus was added at the basal
side of the epithelium, whereas replication was optimal after
inoculation at the apical surface. This suggests that HRVs enter at
the apical side of the upper respiratory epithelium. Immunoﬂuor-
escence with an antibody directed against double-stranded RNA, or
in situ hybridization with peptide nucleic acid-based hybridization
oligoprobe speciﬁc for HRVs and HEVs then showed that both HRV-
Cs and HRV-As present a replication restricted to the upper layers of
the epithelium, thus conﬁrming previous observations (Arruda
et al., 1995; Bochkov et al., 2011; de Arruda et al., 1991; Hao et al.,
2012). Finally, we showed that HRV-Cs exit preferentially from the
apical side of the epithelium. Thus, we postulate that these viruses
infect the upper layers of the respiratory epithelium, replicate in
these superﬁcial layers, and ﬁnally exit at the apical surface. This
would explain in part why HRVs are restricted to the respiratory
tract and do not disseminate in general. It will be interesting to use
this polarized tissue culture system to ﬁnd out whether viruses that
can disseminate after entry via the respiratory route present the
ability to exit preferentially from the basal side of this reconstituted
human airway epithelium.We analyzed the acid sensitivity of HRV-C29 and reproduced
the observation made for HRV-C15 (Ashraf et al., 2012), i.e.,
HRV-Cs appear acid-sensitive, similar to HRV-As and HRV-Bs. We
then compared the optimal growth temperature of strains corre-
sponding to four different HRV-C types used in this study and
found that temperature sensitivity at early time points differed
among the tested clinical strains. Indeed, HRV-C7 and HRV-C29
grew better at 34 1C than at 37 1C 24 h post-inoculation with a
three-log replicative advantage for HRV-C7. Surprisingly, this
advantage was reduced at later time points. Whether this is linked
to viral adaptation after several rounds of replication remains an
open question. The other tested HRV-C types, as well as an HRV-A
clinical strain (HRV-A41), showed a limited or no replicative
advantage at 34 1C, suggesting that optimal growth temperature
may be type-dependent for HRV-Cs as observed previously
for other HRVs. The study by Ashraf et al. showed equivalent
replication for both HRV-C15 and HRV-C41 at 341 and 37 1C
Fig. 5. HRV RNA loads measured at the apical and basal side of MucilAir™. HRV-C2
(VD11-1202-U),–C7 (WA23-1203-U),–C12 (GM09-0909-U), and –C29 (KG11-1202-
U), as well as acid-inactivated HRV-C29 (see Fig. 6), were inoculated at the apical
surface of MucilAir™ and HRV RNA load was quantiﬁed by real-time RT-PCR from
the apical or basal faces of the tissue at the indicated time. Error bars represent the
standard deviation calculated from biological replicates (n¼2). A signiﬁcant P value
(Po0.0001) was observed between apical (n¼16, median 8.61) and basal collec-
tion (n¼16, median 6.28). ninfection with acid-inactivated HRV-C29.
Fig. 6. HRV-A41 (WW74-1202-U) and HRV-C29 (KG11-1202-U) infected clinical
specimens, as well as HRV-A16, and HEV-A71, were preincubated in acidic (pH 4) or
neutral medium (pH 7) before infection of MucilAir™ or Vero cells as indicated.
48 h (HRV) or 24 h (HEV) post-infection, RNA load was quantiﬁed by real-time RT-
PCR from the apical side of polyp tissues or from infected Vero cell supernatants.
Error bars represent the standard deviation calculated from biological replicates
(n¼2).
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cally related (Fig. 1) and may thus belong to a group of HRV-Cs
resistant to higher temperatures. We did not ﬁnd a strict correla-
tion between temperature sensitivity and GC content among the
HRV types tested. This is also the case among other viruses of the
Enterovirus genus. Although most HRV-As and HRV-Bs present a
GC content below 41%, similar to HEV-D68, an enterovirus fre-
quently associated with respiratory infections, other respiratory
enteroviruses present high GC content (48%), such as the recently
discovered HEV-C104, -C109, -C117 and -C118. Inversely, viruses
with low GC content (43%) can cause gastroenteritis, such as
coxsackie A1 and HEV-D70 (Tapparel et al., 2012). Additional
investigations are required to establish a strict link between GC
content and given phenotypes.If some HRV-C types are more resistant to higher body
temperatures, they may have an improved propensity to infect
the lower airways. Genotyping of HRV-C strains found in lower
respiratory tract complications could help to answer this question.
Similarly, HRVs isolated from stools should support higher body
temperatures, in addition to being acidic-resistant. Thus, it will be
of interest to genotype and sequence the complete genome of
HRVs isolated from stool samples (Harvala et al., 2012; Honkanen
et al., 2012; Lau et al., 2012).
In conclusion, we consider this commercially available, stan-
dardized, reconstituted human upper airway epithelium ALI cul-
ture system as a useful tool to model the respiratory epithelium
and to study infections not only caused by HRVs, but also by other
respiratory pathogens. Our observations help to understand some
of the clinical phenotypes observed during natural HRV-C
infections.Materials and methods
Viruses, clinical specimens and sequences
HRV-A16 and HEV-A71 [EU414331] viral stocks were prepared
from infectious clones in Hela Ohio and Vero cells as previously
described (Cordey et al., 2012; Schibler et al., 2012a). Nasophar-
yngeal swabs of patients enrolled in clinical studies approved by
the University of Geneva Hospitals ethics committee and screened
positive for HRV were used for the study. The VP4/VP2 sequences
of these clinical HRV strains were obtained by semi-nested PCR
ampliﬁcation and sequencing with the HRV forward (F484-5'CG-
GCCCCTGAATGYGGCTAA3' and F587sn-5'CTACTTTGGGTGTCCGTG-
TTTC3') and reverse primers (R1126-5'ATCHGGHARYTTCCAMCACCA3')
as previously described (Linsuwanon et al., 2009; Tapparel et al., 2011)
and are available in Genbank (accession numbers KC841446 to
KC841451 and HM347252 and HM347267).Human airway epithelia reconstituted in vitro (MucilAir™)
Nasal polyp epithelial cells were obtained from patients under-
going surgical nasal polypectomy. All experimental procedures
were explained in full, and all subjects provided written informed
consent. The study was conducted according to the Declaration of
Helsinki on biomedical research (Hong Kong amendment, 1989),
and the research protocol was approved by the local ethics
committee.
To reconstitute the human airway epithelium in vitro, low
passage (P0 or P1) primary cells were seeded in 6.5 mm
Transwell-COL inserts (0.4 μm pore size, Costar 3470, Corning
Inc.). Once the cells were attached to the semiporous membrane,
the culture medium was removed from the upper chamber of the
inserts and the cells were then cultured at the air–liquid interface
(ALI culture). After approximately 45 days of culture, the epithelia
became fully differentiated, both morphologically and functionally,
i.e., the epithelium showed a pseudo-stratiﬁed architecture with
the three main types of epithelial cells (ciliated, mucus, and basal
cells). The epithelium showed active cilia-beating and mucociliary
clearance, as well as ion channel activities. Furthermore, once
differentiated, it remains at a homeostasis state for more than one
year. This ALI culture is known commercially as MucilAir™. Some
epithelia were prepared with a mixture of cells originating from
different donors (14 in total), so-called MucilAir™ “pool”, which
were reconstituted in the same way as MucilAir™ and with the
same characteristics. The MucilAir™ pool is available in large
quantities and for several years. The differentiated epithelium
contains approximately 400,000 cells. All inserts were tested
Fig. 7. HRV-A and HRV-Cs clinical specimens were inoculated on MucilAir™ grown at 34 1C or 37 1C and viral load was quantiﬁed from the apical surface at different times
post-infection. The GC content of each of these different viruses was calculated based on the GenBank complete genome sequence of the nearest type (Genbank EF077280 for
HRV-C2, DQ8795932 for HRV-C7, GU219984 for HRV-C12, and DQ473491 for HRV-A41) when available and is indicated in brackets. The error bar indicates the standard
deviation calculated on biological replicates [n¼3 for HRV-C2 (VD11-1202-U), HRV-C12 (GM09-0909-U), HRV-C29 (KG11-1202-U) and HRV-A41 (WW74-1202-U9) and n¼2
for HRV-C7 (WA23-1203-U)]. Po0.0001; P¼0.056, NA: not available.
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yeast, and fungi.
Infection
HRV clinical specimens were either undiluted or diluted in
MucilAir™ ready-to-use culture medium (Epithelix). Before inocu-
lation, MucilAir™ was washed three times with Ca2+-Mg2+-free
phosphate-buffered saline (PBS). Tissues were then either totally
immersed in the viral suspension, or 100 μl or 500 μl of viral
suspension were applied on the apical or basal face, respectively,
of the epithelium. At 4 or 6 h post-incubation at 34 1C or 37 1C,
tissues were rinsed three times with PBS and cultures were
continued in the liquid air interface with 500 μl of fresh culture
medium. For HRV-A16, HRV-A41, HRV-C15, and HRV-C29 types,
successive passages were performed as follows: apical washes
were collected at 48 h post-infection and 1/5 volume was used to
infect new MucilAir™ tissues.
For the acid sensitivity assay, 20 μl of clinical samples contain-
ing HRV-C29, as well as HRV-A41, HRV-A16 and HEV-A71
[EU414331] viral stocks, were diluted in 1 volume (20 μl) of
0.1 M citrate buffer pH 4.0 or 0.1 M of phosphate buffer pH 7.2.
Samples were then incubated for 1 h at 37 1C before neutralization
by the addition of 2 volumes (40 μl) of 0.1 M phosphate buffer pH
7.2 and 6 volumes (120 μl) of culture medium with a ﬁnal 10-fold
dilution of the clinical specimen, and inoculated onto tissues or
Vero cell cultures.
RNA load quantiﬁcation
At different times post-inoculation, an apical wash was col-
lected by applying 200 μl of culture media to the apical surface of
the MucilAir™ and incubating for 20 min at 341 or 37 1C. For
collection from the basal face, the 500 μl culture media was
collected and replaced with fresh media. To quantify cell-
associated viruses, total tissue lysates were collected 4 h or 24 h
post-incubation at 34 1C.For virus RNA load quantiﬁcation, dilutions applied during
sample processing (from extraction to real-time PCR) were taken
into account in the ﬁnal calculation. RNA quantiﬁcation was
performed by one-step real-time RT-PCR as previously described
(Schibler et al., 2012b; Tapparel et al., 2009a). HRV RNA was
measured with the Panenterhino/Ge/08 assay using HRV-14 10-
fold diluted RNA transcript as reference standard, while HEV RNA
was quantiﬁed with the Entero/Ge/08 assay using HEV-71
(EU414331) 10-fold diluted RNA transcript as reference standard.
Canine distemper virus (CDV) was spiked as a control in each
extraction as previously described. For cell-associated virus quan-
tiﬁcation, viral amplicon Ct values were normalized according to
the endogenous RNase P gene (TaqMan RNase P Control Reagents,
ref 4316844, Applied Biosystems).
Immunoﬂuorescence
MucilAir™ infected for 48 h or 10 days by different clinical HRV-
C specimens or HRV-A41 and non-infected epithelia were rinsed
three times with PBS and ﬁxed with 4% paraformaldehyde (PFA)
for 30 min at room temperature. Tissues were then washed twice
with PBS , incubated in ammonium chloride (NH4Cl) solution
(50 mM in PBS, pH 8.0) for 15 min at room temperature, and then
permeabilized with 0.05% Triton X-100 in PBS for a further
15 min. After three washes with PBS containing 1% newborn calf
serum (PBS-NCS), tissues were incubated for 1 h at room tem-
perature with a primary mouse antibody (mAbJ2) (Engscicons, Cat
10010200) targeting double-stranded RNA and validated for wide
HRV detection (Jurgeit et al., 2010). After ﬁve washes, tissues were
incubated with Alexa 594-conjugated secondary anti-mouse IgG
as described (Sobo et al., 2011). Tissues were then washed ﬁve
times with PBS-NCS, incubated in 4', 6-diamino-2-phenylindole
(DAPI), washed ﬁve times with PBS-NCS, and mounted onto glass
slides. Alternatively, immune staining was performed on parafﬁn-
embedded MucilAir™ tissue sections. In this case, parafﬁn was
removed by warming the slices at 95 1C in 100 mM EDTA before
staining.
C. Tapparel et al. / Virology 446 (2013) 1–8 7Images were acquired in multiple sections (0.3 μm/section,
1 μm/section for parafﬁn-embedded slices and total tissues,
respectively) from the apical to the basal pole using a Zeiss LSM
510 Meta confocal laser scanning microscope, and were processed
by Imaris bitplane software as described (Sobo et al., 2012). All
images presented are three-dimensional (3D) projections from the
multisection scannings.
In situ hybridization
Infected MucilAir™was labeled by in situ hybridization with the
PNA ISH detection kit (DakoCytomation, Baar, Switzerland) and a
peptide nucleic acid-based hybridization oligoprobe (Panenter-
hino/Ge/08 PNA probe) designed to detect all HRV and HEV
species members as previously described (Tapparel et al., 2009a).
In brief, tissue sections were rinsed twice with PBS and ﬁxed
with 4% PFA for 30 min at room temperature. After a quick wash
with PBS , tissues were rehydrated in 1 ml PBS for 10 min at
room temperature. They were then permeabilized with proteinase
K (provided with the kit) diluted (1:100) in Tris-buffered saline
(TBS) for 30 min at room temperature in a moisture chamber.
Tissues were rinsed with PBS , brieﬂy ﬁxed again for 5 min with
4% PFA at room temperature, and washed for 5 min in PBS .
Hybridization was carried out according to the guidelines of the kit
provider. The probe was added to the tissues and incubated at
55 1C for 1.5 h followed by four successive washing steps (the ﬁrst
two steps for 10 min and the last ones for 20 min each) using the
stringent washing solution (Dako Permanent Red detection kit) at
60 1C. Hybridization was revealed with the ﬂuorescent red sub-
strate (Dako Permanent Red detection kit). Tissues were incubated
in DAPI for 5 min at RT and mounted onto glass slides for confocal
microscope analysis.
Statistical analysis
To evaluate the statistical signiﬁcance of differences in RNA
quantiﬁcation obtained between two groups, P values were deter-
mined using the t-test (Fig. 7) or the Mann–Whitney test (Fig. 5).
Po0.05 was considered signiﬁcant.Acknowledgments
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